<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887142</url>
  </required_header>
  <id_info>
    <org_study_id>01/20-405</org_study_id>
    <nct_id>NCT04887142</nct_id>
  </id_info>
  <brief_title>Predictors of Disease Severity in COVID-19 Patients</brief_title>
  <acronym>VIRIONUM</acronym>
  <official_title>Biochemical, Inflammatory and Genetic Factors in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeljko Mijailovic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kragujevac</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the VIRIONUM project is to analyze the association of clinical,&#xD;
      socio-demographic characteristics of patients and their genetic polymorphism, inflammatory&#xD;
      and other biochemical markers with disease progression and death in subjects with COVID-19&#xD;
      disease. The research is an observational, cohort study with nested-case control design,&#xD;
      including adult, male and female COVID-19 inpatients. Primary dependent variable will be&#xD;
      outcome of disease, defined as discharge from the hospital or death. The outcomes and&#xD;
      putative risk factors will be analyzed using binary logistic regressions. The proposed multi-&#xD;
      and inter-disciplinary study should provide additional scientific evidence about risk factors&#xD;
      for the development of severe forms of the disease and the COVID-19-related death.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Severe acute respiratory syndrome 2 (SARS-CoV-2) is etiological agent of&#xD;
      heterogeneous corona-virus disease 19 (COVID-19), which clinical condition range from&#xD;
      asymptomatic or mild to critically severe with high odds for fatal outcome. Since the&#xD;
      pathophysiological pathways of COVID-19 disease development are not fully elucidated,&#xD;
      resulting in repeated changes in treatment plans, there is an unmet need for more research&#xD;
      into genetic, biochemical, immunological, and clinical predictive indicators of better&#xD;
      outcomes in COVID-19 patients.&#xD;
&#xD;
      Aim: The VIRIONUM project's main aim is to investigate the relation between genetic&#xD;
      polymorphisms, inflammatory and other biochemical markers, and disease severity and mortality&#xD;
      in COVID-19-infected hospitalized patients.&#xD;
&#xD;
      Method and patients: The observational nested case-control clinical study will be conducted&#xD;
      in at least 1019 COVID-19 patients. The genetic polymorphisms (ACE2, IFNL3/4 and TMPRSS2),&#xD;
      serum concentration of soluble ACE2 and the pro- and anti-inflammatory cytokines, blood&#xD;
      concentration of common inflammatory and other biomarkers, peripheral blood mononuclear&#xD;
      leukocyte (PBMC) phenotype, demographic and clinical risk factors will be monitored as&#xD;
      independent variables, while the dependent variables will be the outcome of the disease and&#xD;
      the severity of the clinical condition. Genotyping will be performed by Real-Time PCR method,&#xD;
      and serum concentrations of ACE2 and pro- and anti-inflammatory cytokines by ELISA method,&#xD;
      and PBMC phenotype by flow cytometry. The disease severity will be assessed according to WHO&#xD;
      criteria.&#xD;
&#xD;
      Expected results: The findings of this clinical study will contribute to understanding of&#xD;
      significant genetic, biochemical, and clinical determinants of severity and lethal outcomes&#xD;
      in COVID-19 patients, as well as, creation of set of recommendations for individuals at&#xD;
      higher risk - future, evidence-based, targeted and individualized approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Fatal Outcome</measure>
    <time_frame>Up to 6 weeks from recruitment to hospital discharge or death</time_frame>
    <description>Case fatality ratio will be calculated as the proportion of patients who died from all causes (all-cause mortality) compared to the total number of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ordinal Scale for Clinical Improvement</measure>
    <time_frame>Up to 6 weeks from recruitment to hospital discharge or death</time_frame>
    <description>Patients' COVID-19 severity and clinical improvement will be assessed according to the recommendations of World Health Organization using Ordinal Scale for Clinical Improvement and the patient state will be classified as mild (score 4 or less) or severe (score 5 or more).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1019</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>The discharged subjects</arm_group_label>
    <description>The COVID-19 inpatients treated with standard care who survived the disease and discharged from hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The deceased subjects</arm_group_label>
    <description>The COVID-19 inpatients treated with standard care who died from the disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of health care</intervention_name>
    <description>The patients in this observational study will be exposed to the standard health care interventions according to the hospital diagnostic and treatment protocols and procedures and clinical judgment of the treating physicians.</description>
    <arm_group_label>The deceased subjects</arm_group_label>
    <arm_group_label>The discharged subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood specimen, serum, white cells.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients of both sexes with different socio-demographic and clinical characteristics,&#xD;
        who were hospitalized due to COVID-19. The decision on hospitalization and further&#xD;
        treatment of patients is at the discretion of the attending physicians. All participants&#xD;
        will be prospectively followed during their hospital stay. Patients will be included in the&#xD;
        study if they are at least 18 years old and if they give voluntary written consent to&#xD;
        participate. Pregnant and breastfeeding women, patients transferred from other hospitals&#xD;
        and those who die during the first 24 hours of hospitalization will be excluded. In this&#xD;
        study, stratification of participants according to age to those older than 65 years and&#xD;
        younger is provided only for the purposes of statistical data processing and analyse.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult age, 18 years old or more&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Hospitalization for COVID-19 after confirmation by SARS-CoV-2 rapid antigen test or&#xD;
             RT-PCR&#xD;
&#xD;
          -  Voluntary written consent of the subject to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and breastfeeding women&#xD;
&#xD;
          -  Fatal outcome during the first 24 hours of hospitalization&#xD;
&#xD;
          -  Inability to collect the necessary study data&#xD;
&#xD;
          -  Declining of the subject to voluntary participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dejan Baskic, MD PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zeljko Mijailovic, MD PhD</last_name>
    <phone>+381 64 1675986</phone>
    <email>drmijailovic70@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dragan Milovanovic, MD PhD</last_name>
    <phone>+38134505050</phone>
    <phone_ext>5254</phone_ext>
    <email>piki@medf.kg.ac.rs</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spitali Amerikan</name>
      <address>
        <city>Tirana</city>
        <country>Albania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lindita Mano, MD PhD</last_name>
      <phone>+355692077045</phone>
      <email>lidashosha@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Prim. dr. Abdulah Naka≈°&quot;</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edin Begic, MD</last_name>
      <phone>+387 33 285 100</phone>
      <email>edinbegic90@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KBC Rijeka, University of Rijeka</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor Barkovic, MD PhD</last_name>
      <phone>+385915374094</phone>
      <email>igor.barkovic@medri.uniri.hr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Montenegro, Faculty of Medicine</name>
      <address>
        <city>Podgorica</city>
        <country>Montenegro</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aneta Boskovic, MD PhD</last_name>
      <phone>+382 20 246651</phone>
      <email>anetab@ucg.ac.me</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty of Medical Sciences, University Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <state>Srbija</state>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dragan Milovanovic, MD PhD</last_name>
      <phone>+381652977831</phone>
      <email>piki@medf.kg.ac.rs</email>
    </contact>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Bosnia and Herzegovina</country>
    <country>Croatia</country>
    <country>Montenegro</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 8, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kragujevac</investigator_affiliation>
    <investigator_full_name>Zeljko Mijailovic</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Inpatients</keyword>
  <keyword>Risk Factors</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Observational Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

